• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

February 8, 2021
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Selva Therapeutics SLV213 nonhospitalized COVID-19 patients completion of phase 1 trial
Valneva VLA2001 COVID-19 vaccine patient enrollment complete in phase 1/2 trial
Arch Biopartners LSALT peptide (Metablok) acute lung injury and acute kidney injury caused by inflammation in patients with severe cases of COVID-19 approval from ethics committee in Turkey to dose 20 additional patients in phase 2 trial
Atea Pharmaceuticals AT-527 mild or moderate COVID-19 patients first patient dosed in phase 2 trial
Biophytis Sarconeos (BIO101) acute respiratory failure associated with COVID-19 initiation of patient recruitment in the U.S. and Brazil in part 2 of phase 2/3 trial
NeuroRx inhaled Zyesami (aviptadil) severe COVID-19 initiation of phase 2/3 trial
Corvus Pharma CPI-006 hospitalized patients with COVID-19 initiation of phase 3 trial
Humanigen lenzilumab hospitalized and hypoxic patients with COVID-19 pneumonia patient enrollment complete in phase 3 trial
Other Trials and Actions
KemPharm KP879 stimulant use disorder IND approved by the FDA
Tetra Bio-Pharma QIXLEEF cancer patients with breakthrough pain IND approved by the FDA
Vertex Pharmaceuticals VX-880 type 1 diabetes IND approved by the FDA
Crinetics Pharmaceuticals CRN04894 Cushing’s disease and congenital adrenal hyperplasia initiation of phase 1 trial
Daiichi Sankyo DS-6000 patients with advanced renal cell carcinoma or ovarian cancer with disease progression following standard treatment first patient dosed in phase 1 trial
Dynavax

Serum Institute of India
tetanus, diphtheria and acellular pertussis (Tdap) booster vaccine adjuvanted with CpG 1018 prevention of tetanus, diphtheria and acellular pertussis first patient dosed in phase 1 trial
Kira Pharmaceuticals P014 complement-mediated diseases first patient dosed in phase 1 trial
LB Pharmaceuticals LB-102 acute schizophrenia first patient dosed in phase 1b trial
BridgeBio Pharma

Venthera
BBP-68/ VT30 topical gel patients with venous, lymphatic and venolymphatic malformations first patient dosed in phase 1/2 trial
Exonate

Johnson & Johnson
EXN 407 center-involved diabetic macular edema first patient dosed in phase 1b/2 trial
ImCyse IMCY-0098 recent onset type 1 diabetes first patients dosed in phase 1b/2a trial
Sio Gene Therapies AXO-AAV-GM2 GM2 gangliosidosis first patient dosed in phase 1/2 trial
Spark Therapeutics SPK-3006 late-onset Pompe disease first patient dosed in phase 1/2 trial
Chemomab CM-101 primary sclerosing cholangitis first patient enrolled in phase 2a trial
Gemini Therapeutics GEM103 patients with wet AMD who have, or may be at risk for, macular atrophy but require ongoing anti-VEGF treatment initiation of phase 2a trial
ADC Therapeutics camidanlumab tesirine (ADCT-301) relapsed or refractory Hodgkin lymphoma completion of patient enrollment in phase 2 trial
Curis CA-4948 anemia in patients with very low-, low- or intermediate-risk myelodysplastic syndromes initiation of phase 2 trial
Daiichi Sankyo patritumab deruxtecan patients with EGFR-mutated metastatic or locally advanced nonsmall-cell lung cancer previously treated with a TKI and platinum-based chemotherapy initiation of phase 2 trial
I-Mab TJ107 (efineptakin alpha) glioblastoma multiforme first patients dosed in phase 2 trial in China
Surface Ophthalmics SURF-200 (betamethasone in Klarity vehicle) acute dry eye first patients dosed in phase 2 trial
Viacyte VC01-103, encapsulated cell therapy type 1 diabetes first patients dosed in phase 2 trial
Arena Pharmaceuticals etrasimod moderately to severely active ulcerative colitis patient enrollment complete in phase 3 trial
Novan SB206 molluscum contagiosum patient enrollment complete in phase 3 trial
VectivBio apraglutide short bowel syndrome first patient dosed in phase 3 trial
Chinook Therapeutics CHK-336 primary hyperoxaluria Rare Pediatric Disease designation granted by the FDA
Cerecor CERC-803 leukocyte adhesion deficiency type II Fast-Track designation granted by the FDA
Gan & Lee Pharmaceuticals GLR2007 glioblastoma Fast-Track designation granted by the FDA
Theratechnologies TH1902 sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy Fast-Track designation granted by the FDA
Adamas Pharmaceuticals Gocovri (amantadine) extended-release capsules adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing OFF episodes approved by the FDA for expanded indication
Biocryst Pharma Rapivab (peramivir injection) acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days approved by the FDA for expanded indication
Biogen Plegridy (peginterferon beta-1a) relapsing forms of multiple sclerosis approved by the FDA for new intramuscular injection route of administration
DURECT Posimir (bupivacaine solution) postsurgical pain for up to 72 hours following arthroscopic subacromial decompression approved by the FDA
Galderma Restylane Defyne chin augmentation approved by the FDA
Johnson & Johnson TECNIS Eyhance and TECNIS Eyhance Toric II intraocular lens cataract patients with or without astigmatism approved by the FDA
Medtronic DiamondTemp Ablation (DTA) system patients with recurrent, symptomatic paroxysmal atrial fibrillation and who have been unresponsive to drug therapy approved by the FDA
Merck KGaA Tepmetko (tepotinib) adults with metastatic nonsmall-cell lung cancer who have a MET exon 14 skipping alteration approved by the FDA
Soliton Rapid Acoustic Pulse technology short-term improvement in the appearance of cellulite approved by the FDA
Astellas Xospata (gilteritinib) relapsed or refractory acute myeloid leukemia with a FLT3 mutation approved in China
Innovent

Eli Lilly
Tyvyt (sintilimab injection) in combination with pemetrexed and platinum chemotherapy first-line therapy for nonsquamous nonsmall-cell lung cancer approved in China for new indication

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing